| Phase II and III randomized clinical trials have demonstrated the efficacy of CGRP-targeted mAbs and gepants for the treatment of migraine. |
| Open-label extension and real-world data studies have demonstrated a favorable safety and tolerability profile of both drug classes. |
| Additional randomized controlled trials and open-label extension studies are currently underway, including the investigation of a new third-generation gepant. |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.